Results 11 to 20 of about 30,099 (284)

Pharmacology of HIV integrase inhibitors [PDF]

Current Opinion in HIV and AIDS, 2012
The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).
Jessica L, Adams, Benjamin N, Greener, Angela D M, Kashuba   +2 more
openaire   +3 more sources

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025 [PDF]

Eurosurveillance
Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025.
Marc van der Valk
doaj   +2 more sources

Treatment of HIV Infections with HIV Integrase Inhibitors [PDF]

ACS Medicinal Chemistry Letters, 2016
Abdel-Magid AF.
openaire   +3 more sources

Authentic HIV-1 Integrase Inhibitors [PDF]

Future Medicinal Chemistry, 2010
HIV-1 integrase (IN) is indispensable for HIV-1 replication and has become a validated target for developing anti-AIDS agents. In two decades of development of IN inhibition-based anti-HIV therapeutics, a significant number of compounds were identified as IN inhibitors, but only some of them showed antiviral activity.
Chenzhong, Liao, Christophe, Marchand, Terrence R, Burke, Yves, Pommier, Marc C, Nicklaus   +4 more
openaire   +2 more sources

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

Structural Biology of HIV Integrase Strand Transfer Inhibitors

Trends in Pharmacological Sciences, 2020
I.K. Jozwik, Dario Oliveira Passos, Dmitry Lyumkis   +2 more
openalex   +4 more sources

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay

Viruses, 2021
Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN).
Steven J. Smith, Andrea Ferris, Xuezhi Zhao, Gary Pauly, Joel P. Schneider, Terrence R. Burke, Stephen H. Hughes   +6 more
doaj   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj   +1 more source

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

Retrovirology, 2009
Background Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes ...
Kuhl Björn D, Donahue Daniel A, Faltenbacher Verena H, Sloan Richard D, Bar-Magen Tamara, Oliveira Maureen, Xu Hongtao, Wainberg Mark A   +7 more
doaj   +1 more source

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel, Borch, Alexandra, De Scheerder, Marie-Angélique, De Spiegelaere, Ward, Koenig, Renate, Malatinková, Eva, Melkova, Zora, Vandekerckhove, Linos   +7 more
core   +1 more source